These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29766362)

  • 21. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
    Nuciforo P; Pascual T; Cortés J; Llombart-Cussac A; Fasani R; Paré L; Oliveira M; Galvan P; Martínez N; Bermejo B; Vidal M; Pernas S; López R; Muñoz M; Garau I; Manso L; Alarcón J; Martínez E; Rodrik-Outmezguine V; Brase JC; Villagrasa P; Prat A; Holgado E
    Ann Oncol; 2018 Jan; 29(1):170-177. PubMed ID: 29045543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
    Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
    Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.
    Criscitiello C; Vingiani A; Maisonneuve P; Viale G; Viale G; Curigliano G
    Breast Cancer Res Treat; 2020 Sep; 183(2):347-354. PubMed ID: 32621251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The value of tumor-infiltrating lymphocytes and CD8 expression as a predictor of response to anthracycline-based neoadjuvant chemotherapy in invasive breast carcinoma of no special type.
    Miskad UA; Rifai RA; Masadah R; Nelwan B; Ahmad D; Cangara H; Prihantono P; Zainuddin AA; Rahawarin H
    Breast Dis; 2021; 40(S1):S9-S14. PubMed ID: 34092582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
    Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
    Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.
    Kotoula V; Chatzopoulos K; Lakis S; Alexopoulou Z; Timotheadou E; Zagouri F; Pentheroudakis G; Gogas H; Galani E; Efstratiou I; Zaramboukas T; Koutras A; Aravantinos G; Samantas E; Psyrri A; Kourea H; Bobos M; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
    Oncotarget; 2016 Jan; 7(4):5074-87. PubMed ID: 26506242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
    Szijgyarto Z; Flach KD; Opdam M; Palmieri C; Linn SC; Wesseling J; Ali S; Bliss JM; Cheang MCU; Zwart W; Coombes RC
    Breast Cancer Res Treat; 2019 May; 175(1):149-163. PubMed ID: 30680659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration.
    Liu S; Foulkes WD; Leung S; Gao D; Lau S; Kos Z; Nielsen TO
    Breast Cancer Res; 2014 Sep; 16(5):432. PubMed ID: 25193543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome Prediction After Neoadjuvant Chemotherapy (NAC) for Breast Cancer, Using Tumor-infiltrating Lymphocytes Within Fibrotic Foci of Tumor Stroma (FF-TILs).
    Kashiwagi S; Asano Y; Takada K; Goto W; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
    Anticancer Res; 2022 Mar; 42(3):1421-1431. PubMed ID: 35220235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
    Noske A; Möbus V; Weber K; Schmatloch S; Weichert W; Köhne CH; Solbach C; Ingold Heppner B; Steiger K; Müller V; Fasching P; Karn T; van Mackelenbergh M; Marmé F; Schmitt WD; Schem C; Stickeler E; Loibl S; Denkert C
    Eur J Cancer; 2019 Jun; 114():76-88. PubMed ID: 31075727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of tumour-infiltrating lymphocytes based on the evaluation of frequency in patients with oestrogen receptor-positive breast cancer.
    He J; Fu F; Wang W; Xi G; Guo W; Zheng L; Ren W; Qiu L; Huang X; Wang C; Li L; Kang D; Chen J
    Eur J Cancer; 2021 Sep; 154():217-226. PubMed ID: 34293665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
    Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
    Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis.
    Mao Y; Qu Q; Chen X; Huang O; Wu J; Shen K
    PLoS One; 2016; 11(4):e0152500. PubMed ID: 27073890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Follow-Up of the Intergroup Exemestane Study.
    Morden JP; Alvarez I; Bertelli G; Coates AS; Coleman R; Fallowfield L; Jassem J; Jones S; Kilburn L; Lønning PE; Ortmann O; Snowdon C; van de Velde C; Andersen J; Del Mastro L; Dodwell D; Holmberg S; Nicholas H; Paridaens R; Bliss JM; Coombes RC
    J Clin Oncol; 2017 Aug; 35(22):2507-2514. PubMed ID: 28467729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.
    Fontein DB; Seynaeve C; Hadji P; Hille ET; van de Water W; Putter H; Kranenbarg EM; Hasenburg A; Paridaens RJ; Vannetzel JM; Markopoulos C; Hozumi Y; Bartlett JM; Jones SE; Rea DW; Nortier JW; van de Velde CJ
    J Clin Oncol; 2013 Jun; 31(18):2257-64. PubMed ID: 23610112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
    Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
    Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Value of Tumor Infiltrating Lymphocytes in Locally Advanced HER2 Enriched Breast Cancer.
    Saber MM; El Zawahry HM; Hilal AM; Abou-Bakr AA; Namour AE; Saber MM
    Asian Pac J Cancer Prev; 2022 Feb; 23(2):553-560. PubMed ID: 35225468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG).
    Balermpas P; Rödel F; Rödel C; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Gkika E; Stuschke M; Avlar M; Grosu AL; Abdollahi A; Debus J; Bayer C; Stangl S; Belka C; Pigorsch S; Multhoff G; Combs SE; Mönnich D; Zips D; Fokas E
    Int J Cancer; 2016 Jan; 138(1):171-81. PubMed ID: 26178914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.